Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Next Previous
Search
Trial Profile

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ligelizumab (Primary) ; Omalizumab
  • Indications Chronic urticaria
  • Focus Registrational; Therapeutic Use
  • Acronyms Pearl 1
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 23 Nov 2023 Results assessing efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria in two phase III trials PEARL-1 and PEARL-2 published in the Lancet.
    • 27 Feb 2023 Results assessing eficacy and safety of ligelizumab from PEARL-1 and PEARL-2 studies were presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 28 Jul 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top